Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,220 GBX | -0.21% | -0.34% | +15.30% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
Business Summary
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Number of employees: 89,900
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncology
37.4
%
| 11,878 | 33.0 % | 13,793 | 37.4 % | +16.12% |
Cardiovascular, Renal and Metabolism
23.1
%
| 7,459 | 20.7 % | 8,515 | 23.1 % | +14.16% |
Rare Disease
16.9
%
| 5,726 | 15.9 % | 6,246 | 16.9 % | +9.08% |
Respiratory and Immunology
13.3
%
| 4,680 | 13.0 % | 4,913 | 13.3 % | +4.97% |
Alliance
3.1
%
| - | - | 1,149 | 3.1 % | - |
Other Medicines
2.6
%
| 1,319 | 3.7 % | 946 | 2.6 % | -28.29% |
Vaccines and Immune Therapies
2.2
%
| 3,845 | 10.7 % | 814 | 2.2 % | -78.83% |
Collaboration
1.3
%
| 1,098 | 3.1 % | 478 | 1.3 % | -56.50% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
39.6
%
| 14,027 | 39.0 % | 14,578 | 39.6 % | +3.93% |
China
12.8
%
| 4,662 | 12.9 % | 4,724 | 12.8 % | +1.32% |
Japan
7.9
%
| 3,236 | 9.0 % | 2,928 | 7.9 % | -9.51% |
United Kingdom
7.4
%
| 2,530 | 7.0 % | 2,709 | 7.4 % | +7.07% |
Other Rest of Europe
6.8
%
| 2,197 | 6.1 % | 2,502 | 6.8 % | +13.89% |
Germany
4.6
%
| 1,544 | 4.3 % | 1,689 | 4.6 % | +9.36% |
Other Asia, Africa and Australasia
4.5
%
| 1,953 | 5.4 % | 1,645 | 4.5 % | -15.77% |
Sweden
3.7
%
| 1,397 | 3.9 % | 1,371 | 3.7 % | -1.89% |
Other Americas
3.7
%
| 954 | 2.6 % | 1,354 | 3.7 % | +41.94% |
France
2.5
%
| 899 | 2.5 % | 927 | 2.5 % | +3.12% |
Canada
2.1
%
| 947 | 2.6 % | 778 | 2.1 % | -17.82% |
Spain
1.8
%
| 599 | 1.7 % | 681 | 1.8 % | +13.73% |
Italy
1.8
%
| 597 | 1.7 % | 654 | 1.8 % | +9.61% |
Australia
0.9
%
| 464 | 1.3 % | 314 | 0.9 % | -32.32% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
Regina Danielson
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Chief Tech/Sci/R&D Officer | - | 23-05-17 | |
Pam Cheng
COO | Chief Operating Officer | 53 | 15-05-31 |
Jeffrey Pott
CMP | Compliance Officer | - | 94-12-31 |
Corporate Officer/Principal | 63 | 01-12-31 | |
Iskra Reic
PRN | Corporate Officer/Principal | - | 00-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
Director/Board Member | 68 | 99-03-31 | |
Marc Dunoyer
PRN | Corporate Officer/Principal | 71 | 13-05-31 |
Andreas Rummelt
BRD | Director/Board Member | 66 | 21-07-31 |
Michel Demaré
CHM | Chairman | 67 | 19-08-31 |
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Deborah DiSanzo
BRD | Director/Board Member | 64 | 17-11-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,550,235,025 | 1,497,890,686 ( 96.62 %) | 0 | 96.62 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
18,750,000 | 75.00% | 1,200,298,875 $ | |
32,100,518 | 9.06% | 834,691,151 $ | |
108,923,023 | 37.58% | 677,619,929 $ | |
NIOX GROUP PLC 16.81% | 71,065,878 | 16.81% | 63,179,698 $ |
CELLECTIS S.A. 22.30% | 16,000,000 | 22.30% | 41,657,920 $ |
ADC THERAPEUTICS SA 4.84% | 4,011,215 | 4.84% | 17,809,795 $ |
INNATE PHARMA 9.26% | 7,485,500 | 9.26% | 17,648,563 $ |
44,803 | 3.62% | 519,715 $ | |
884,956 | 1.99% | 57,522 $ |
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.co.ukGroup companies
Name | Category and Sector |
---|---|
R&Q Beta Co. Plc
R&Q Beta Co. Plc Insurance Brokers/ServicesFinance R&Q Beta Co. Plc provides insurance services. The company was founded in 1994 and is headquartered in Cambridge, the United Kingdom. |
Insurance Brokers/Services
|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. |
Miscellaneous Commercial Services
|
Alexion Pharmaceuticals, Inc. /New/
| |
Astrazeneca Finance & Holdings, Inc.
Astrazeneca Finance & Holdings, Inc. Financial ConglomeratesFinance Part of AstraZeneca PLC, Astrazeneca Finance & Holdings, Inc. is an investment holding American company. The private company is located in the US. |
Financial Conglomerates
|
AstraZeneca India Pvt Ltd.
AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology AstraZeneca India Pvt Ltd. operates as a biopharmaceutical company. The company was founded in 1979 and is headquartered in Bangalore, India. |
Pharmaceuticals: Major
|
Astrazeneca Treasury Ltd.
Astrazeneca Treasury Ltd. Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Treasury Ltd. functions as an investment holding British company. The private company is based in Cambridge, UK. |
Financial Conglomerates
|
Astrazeneca Holdings BV
| |
Astrazeneca Treasury BV
| |
AstraZeneca Employee Share Trust Ltd.
AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The private company is located in the UK. |
Miscellaneous Commercial Services
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.58% | 239B | |
+31.92% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+10.09% | 210B | |
-6.91% | 200B | |
+8.12% | 167B | |
-1.42% | 161B | |
+1.73% | 124B |
- Stock Market
- Equities
- AZN Stock
- Company AstraZeneca PLC